Life (Nov 2022)

Changing Landscape of Liver Transplantation in the Post-DAA and Contemporary ART Era

  • Huma Saeed,
  • Edison J. Cano,
  • Mohammad Qasim Khan,
  • Zachary A. Yetmar,
  • Byron Smith,
  • Stacey A. Rizza,
  • Andrew D. Badley,
  • Maryam Mahmood,
  • Michael D. Leise,
  • Nathan W. Cummins

DOI
https://doi.org/10.3390/life12111755
Journal volume & issue
Vol. 12, no. 11
p. 1755

Abstract

Read online

Combination anti-retroviral therapy has drastically improved solid organ transplantation outcomes in persons living with HIV. DAA therapy has led to the successful eradication of HCV. While recent data have suggested improvement in outcomes in HIV/HCV-coinfected liver transplant recipients, temporal trends in patient survival within pre- and post-DAA eras are yet to be elucidated. The UNOS database was utilized to identify deceased donor liver transplant recipients between 1 January 2000 and 30 September 2020 and stratify them by HIV and HCV infection status. A total of 85,730 patients met the inclusion criteria. One-year and five-year patient survival improved (93% and 80%, respectively) for all transplants performed post-2015. For HIV/HCV-coinfected recipients, survival improved significantly from 78% (pre-2015) to 92% (post-2015). Multivariate regression analyses identified advanced recipient age, Black race, diabetes mellitus and decompensated cirrhosis as risk factors associated with higher one-year mortality. Liver transplant outcomes in HIV/HCV-coinfected liver transplant recipients have significantly improved over the last quinquennium in the setting of the highly effective combination of ART and DAA therapy. The presence of HIV, HCV, HIV/HCV-coinfection and active HCV viremia at the time of transplant do not cause higher mortality risk in liver transplant recipients in the current era.

Keywords